Sharon Osbourne Decides To Quit 'Miracle' Weight Loss Drug Ozempic: 'I Didn't Want To Go This Thin'

TV personality, Sharon Osbourne, has decided to quit using the popular weight loss drug, Ozempic, after losing more weight than she originally intended, DNyuz reported.

The 70-year-old shared her decision during her appearance on Talk TV’s “Piers Morgan Uncensored” alongside her husband Ozzy and children, Kelly and Jack.

“I’ve lost 42 pounds now and it’s just enough. It’s just time to stop, I didn’t actually want to go this thin but it just happened,” Osbourne told Morgan.

However, she added that she would start taking Ozempic again later.

See Also: Tiktok ‘Budget Ozempic’ Trend Sparks Health Concerns: ‘Really Worrying’

The former “America’s Got Talent” host also detailed her experience with using Ozempic. She described initial nausea and loss of appetite. She urged caution to others considering the drug, particularly the younger demographic.

Osbourne disclosed her use of the “injection that everybody takes” to lose weight on the “Club Random with Bill Maher” podcast last month. She highlighted the side effects she experienced, including constant nausea.

The former talk show host had previously used injectable weight loss drugs to shed 30 pounds earlier this year, as she shared on “The Talk UK” in May.

Read Next: If you don't take a look, you'll miss out: The list of startups you can invest in is here. Click here to take the leap into the world of startup investing.

Image By Natalia Varlei On Shutterstock


Engineered by Benzinga Neuro, Edited by Pooja Rajkumari


The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMediaGeneralOzempicSharon Osbourneweightloss
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...